āĻšā§āĻŽMOLN âĸ NASDAQ
add
Molecular Partners AG
ā§Ē.ā§Ŧā§Ž$
ā§Ē āĻŽāĻžāĻ°ā§āĻ, ā§¯:ā§Šā§¨:ā§Ļā§Ļ AM GMT -ā§Ģ · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§Ģ.ā§Ļā§Š$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§Ē.ā§Ŧā§Ž$ - ā§Ē.ā§Ŧā§Ž$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§Š.ā§Šā§¨$ - ā§§ā§¨.ā§ā§Ļ$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§§ā§Ž.ā§Ģā§Ģ āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§§.ā§Žā§ŽÂ āĻšāĻž
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
(CHF) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ŧ.ā§Žā§§Â āĻ˛āĻž | -ā§ā§Š.ā§¨ā§Ļ% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§Ēā§Ē.ā§Ļā§Ŧ āĻ˛āĻž | -ā§Ļ.ā§Šā§Ž% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§.ā§Ŧā§Ē āĻā§ | -ā§Ēā§Š.ā§Ēā§Ļ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | -ā§¨.ā§Ēā§§Â āĻšāĻž | -ā§Ēā§Šā§Ģ.ā§Ļā§Ž% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | -ā§Ļ.ā§Ēā§¯ | â |
EBITDA | -ā§§.ā§Ēā§Ļ āĻā§ | -ā§Ž.ā§Ŧā§Ē% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | â | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(CHF) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§§ā§Ē.ā§Šā§Ŧ āĻā§ | -ā§Šā§Ļ.ā§Ēā§¯% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§§ā§Ģ.ā§Ēā§¨Â āĻā§ | -ā§¨ā§¯.ā§Šā§Ļ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§§.ā§Ģā§Ē āĻā§ | -ā§¨ā§¯.ā§Ģā§Ŧ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§Š.ā§Žā§ŽÂ āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Š.ā§Šā§¨Â āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§§.ā§¨ā§Ļ | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§¨ā§¨.ā§Ēā§Ŧ% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | -ā§¨ā§Ē.ā§Šā§Ļ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
(CHF) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§.ā§Ŧā§Ē āĻā§ | -ā§Ēā§Š.ā§Ēā§Ļ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | -ā§§.ā§Šā§ŠÂ āĻā§ | -ā§Ļ.ā§Ŧā§Ž% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§§.ā§Ēā§¨Â āĻā§ | -ā§¨ā§Ļ.ā§Ļā§Ļ% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§Š.ā§Ļā§§Â āĻ˛āĻž | -ā§§.ā§Ļā§§% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | ā§Ŧā§Ŧ.ā§Ļā§Ļ āĻšāĻž | -ā§¯ā§Ž.ā§ā§¨% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | -ā§Žā§Ļ.ā§¯ā§Ļ āĻ˛āĻž | -ā§Ē.ā§§ā§¯% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Molecular Partners AG is a clinical-stage biopharmaceutical company based in ZÃŧrich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§Ļā§Ļā§Ē
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§§ā§Ŧā§¨